Sébastien Enault

Sébastien Enault is the current Chief Business Officer at MedinCell. Sébastien has also served as the Chief Business Development Officer at DEINOVE and Eligo Bioscience.

Sébastien has over 15 years of experience in business development and corporate development activities. Sébastien has a proven track record in leading and executing successful business development strategies.

Some of Sébastien's key achievements include leading Deinove to a successful capital increase of € 8.5 million, acquiring the MCB3681 / MCB3837 clinical-stage antibiotic compound and Morphochem company, and setting up a research collaboration agreement with the Pasteur Institute.

Under Sébastien's leadership, Eligo Bioscience raised €18.5 million in Series A funding from Khosla Ventures and Seventure Partners.

Sébastien holds a Master's degree in Business Administration from HEC Paris.

Sébastien Enault has a BSc from Avignon Université, a Master's degree from Université Nice Sophia Antipolis (membre d'Université Côte d'Azur), and an MSc and Pharmacology Engineering Diploma from École Polytechnique. Theirfield of study is pharmacology.